news 2023
« BACK
Health - Pharmacology - 25.01.2023
Health - Pharmacology - 20.01.2023 
Private patients receive treatment for heart conditions more often than those with basic health insurance
Patients in Switzerland with supplementary private health insurance are more likely to undergo cardiac procedures than those with only basic health insurance. This has been demonstrated in a study by researchers from the University of Basel and the Cantonal Hospital of Aarau. Switzerland has one of the most expensive healthcare systems in the world.
Health - Pharmacology - 13.01.2023
Pharmacology - Health - 12.01.2023 
Financial incentives for vaccination do not have unintended negative consequences
Contrary to warnings in the academic literature and public debate, modest financial incentives for vaccination can be used without fear of serious unintended consequences. This is the result of a scientific study, published in "Nature", conducted by the University of Zurich, Lund University and Unisanté.
Pharmacology
Results 1 - 4 of 4.
New treatment of hepatic disorders of abnormal lipid deposition
The Experimental Therapeutics group , directed by Prof. Carlo V. Catapano at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), in collaboration with Prof. Jonathan Hall at the Swiss Federal Institute of Technology in Zürich (ETH, Zurich) identified a novel mechanism for the treatment of hepatic disorders of abnormal lipid deposition.
The Experimental Therapeutics group , directed by Prof. Carlo V. Catapano at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), in collaboration with Prof. Jonathan Hall at the Swiss Federal Institute of Technology in Zürich (ETH, Zurich) identified a novel mechanism for the treatment of hepatic disorders of abnormal lipid deposition.
Patients in Switzerland with supplementary private health insurance are more likely to undergo cardiac procedures than those with only basic health insurance. This has been demonstrated in a study by researchers from the University of Basel and the Cantonal Hospital of Aarau. Switzerland has one of the most expensive healthcare systems in the world.
Drug combo breaks down cancer resistance to immunotherapy
By combining a checkpoint inhibitor with a new immunocytokine, scientists at EPFL, Ludwig Institute for Cancer Research, CHUV and Roche have made a breakthrough in fighting against immunotherapy-resistant cancers. Immunotherapy is a way of treating cancer by reprogramming the patient's immune system to attack their tumor.
By combining a checkpoint inhibitor with a new immunocytokine, scientists at EPFL, Ludwig Institute for Cancer Research, CHUV and Roche have made a breakthrough in fighting against immunotherapy-resistant cancers. Immunotherapy is a way of treating cancer by reprogramming the patient's immune system to attack their tumor.
Contrary to warnings in the academic literature and public debate, modest financial incentives for vaccination can be used without fear of serious unintended consequences. This is the result of a scientific study, published in "Nature", conducted by the University of Zurich, Lund University and Unisanté.
